Coenzyme Q (CoQ) also known as ubiquinone, is a lipid molecule widely distributed in nature. In mitochondria, like in other cellular compartments, it
is present both in its oxidised state (ubiquinone) and in its reduced one (ubiquinol) . The first homolog to be discovered about 50 years ago, in beef mitochondria, was coenzyme Q 10 (Crane et al., 1957) . In fact, CoQ is made of benzoquinone moiety and an isoprenoid side chain the length of which is 10 units both in man and many mammals; therefore we talk about CoQ 10 and reduced CoQ 10 (ubiquinol-10). Other living organisms possess different species of CoQ, for instance Saccharomyces cerevisiae produces CoQ 6 , other microorganisms CoQ 7 , and many mammals CoQ 9 . Each organism possesses a dominant homolog of CoQ, and minor amounts of other homologs. Most of CoQ 10 available as a food supplement is natural CoQ 10 , extracted from some microorganisms which synthesize CoQ 10 , identical to the one which is found in humans and other mammals. This issue will be commented later on in the text.
For a certain number of years CoQ was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in plasma, and extensively investigated its antioxidant role. The rationale supporting the use of CoQ 10 as a food supplement is mainly based on these two functions. More recent data reveal that CoQ 10 affects the expression of genes involved in human cell signalling, metabolism and transport (Groneberg et al., 2005) and some of the effects of exogenously administered CoQ 10 may be due to this property.
New progress has been made in elucidating CoQ 10 in metabolism and nutrition. This short chapter is mainly focused on recent findings which will hopefully contribute to better understand the relationship between basic biochemical mechanisms and certain physiological and clinical effects.
CoQ 10 and mitochondrial bioenergetics
The essential role of CoQ 10 in bioenergetics was postulated since the years of its discovery. In fact several years later, the studies of Nobel Prize winner Peter Mitchell highlighted the central role of this quinone in the chemoosmotic production of ATP. Therefore CoQ 10 is a key component of the mitochondrial machinery, the main Abstract: Coenzyme Q is a lipid molecule widely diffused in nature; in humans and other mammals it is present as coenzyme Q 10 . (CoQ 10 ). The first recognized role of CoQ 10 was in mitochondrial bioenergetics, where it plays a central role in the production of ATP. It is also present in other subcellular organelles, both in its oxidized and in its reduced state (ubiquinol-10). The reduced form of CoQ 10 is endowed with powerful antioxidant activity: it acts as a chain-breaking antioxidant and is also capable of regenerating alpha-tocopherol, the active form of vitamin E. By these mechanisms CoQ 10 , together with vitamin E, protects lipoproteins from oxidation a process which bears considerable interest in preventing atherosclerosis. CoQ 10 has also been found to support cardiovascular function and the latest findings indicate an active role in counteracting endothelial dysfunction, which is closely implicated in cardiovascular disease. CoQ 10 also improves sperm motility, an effect which might be related both to its antioxidant and to its bioenergetic properties. Oxidative stress might be involved in neurodegenerative disease, and in migraine, two fields where the positive effects of CoQ 10 have been documented. CoQ 10 is synthesized by our body but is also present in food and can be taken as a nutritional supplement. The main source of industrially produced CoQ 10 is yeast fermentation. The process results in CoQ 10 which is identical to the naturally occurring molecule. Ubiquinol, the reduced form of CoQ 10 , has recently become available.
energy plant of our cells. At this level it operates as a redox couple (ubiquinone/ ubiquinol), responsible for proton and electron transport. If mitochondria are devoid of CoQ 10 they cannot produce ATP; in some conditions we can have partial CoQ 10 deficiencies.
Even though the concentration of CoQ 10 in mitochondria is rather high compared to the corresponding concentration of other mitochondrial components, it is not saturating. This practically means that at the actual concentrations of CoQ 10 in these membranes the velocity of the respiratory complexes is not the maximal one. In fact, small variations in the concentration of CoQ 10 in these membranes leads to remarkable changes in the respiratory rates of these cells. This can explain why, even though a small part of the exogenously administered CoQ 10 is uptaken by our cells, the effect is not negligible (figure 1).
Ubiquinone biosynthesis: biochemical and clinical implications
Strictly speaking CoQ 10 is not a vitamin, as mammals and lower animals are capable of synthesizing this molecule.
A minor part is however introduced through the diet; moreover a series of dietary components is essential for the proper functioning of CoQ 10 biosynthesis (figure 2).
The synthesis of the quinone moiety of CoQ 10 starts from phenylalanine or from tyrosine and the isoprenoid side chain derives from mevalonate. A series of vitamin cofactors is needed for this biosynthesis. According to Karl Folkers the dominant source of CoQ 10 in man is biosynthesis. This complex, 17 step process, requiring at least seven vitamins (vitamin B2 -riboflavin, vitamin B3 -niacinamide, vitamin B6, folic acid, vitamin B12, vitamin C, and pantothenic acid) and several trace elements, is, by its nature, highly vulnerable. Karl Folkers argues that suboptimal nutrient intake in man is highly possible and that there is subsequent secondary impairment in CoQ 10 biosynthesis. It was highlighted that in a vitamin B6 deficiency plasma CoQ 10 levels are also low and they increase upon improvement of the vitamin B6 deficiency status (Willis et al., 1999) . In eukaryotes the isoprenoid side chain of coenzyme Q is synthesized through the mevalonate pathway, which also leads to the synthesis of cholesterol. As we will comment below statins, the potent and widely used anticholesterolemic drugs, also inhibit CoQ 10 biosynthesis and this could have important practical implications.
Coenzyme Q 10 concentration greatly varies in different tissues, probably related to different metabolic demands (figure 3).
Tissue concentrations of CoQ 10 also vary with age: for different organs an increase of CoQ 10 has been found in the initial decades with a subsequent decrease (figure 4).
CoQ as an antioxidant
In its reduced form (ubiquinol) coenzyme Q acts as a phenolic antioxidant, undergoing hydrogen abstraction by free radicals, therefore it acts like a chain breaking antioxidant. This evidence has been produced by numerous experimental models, both in vivo and in vitro, using artificial membranes, isolated subcellular organelles, cultured cells, isolated perfused organs and clinical models (Dallner and Stocker, 2005) .
Ubiquinol may act by slowing down the chain propagation reaction, with a mechanism that is common to the cocalled ''chain breaking antioxidants''. Reduced Coenzyme Q is also able to regenerate a-tocopherol, the active form of Vitamin E: in this sense CoQ 10 and vitamin E are considered as a lipophilic antioxidant duo of primary importance. In order to act as an antioxidant CoQ must be in the reduced state; several enzymes exert this function of CoQ reductases. There are some conditions where the reducing capacity of the cell might be impaired: in these conditions supplementing CoQ 10 already in the reduced state (QH 2 , ubiquinol-10) might be particularly relevant.
Antioxidant function of CoQ 10 in plasma lipoproteins
It is currently believed that high levels of LDL, as well as smoking and hypertension, are primary risk factors, among those contributing to cardiovascular disease.
Biochemical mechanisms responsible for the atherogenicity of LDL have been extensively addressed, and experimental evidence bas been produced indicating that oxidatively modified LDL become atherogenic. It was found that endothelial cells are involved in the oxidative attack against LDL. Oxidative attack on LDL deeply affects the apoprotein moiety as well. As a consequence of these changes LDL are no longer ''recognized'' by the normal receptors, and are taken up more readily by the scavenger receptors of macrophages. LDL leave the blood stream, penetrate the endothelial cell lining and reach the subendothelial space, where they undergo oxidative attack. Oxidatively modified LDL are capable of triggering further events, including platelet activation, and exert a chemotactic attraction on circulating monocytes, which migrate to the subendothelial space, where they become macrophages. These cells have only low levels of the classical LDL receptor, nonetheless they are able to take up more rapidly oxidatively modified LDL, and this uptake involves a different receptor, called the ''scavenger receptor''. As discussed above, oxidatively modified LDL are easily recognized by the scavenger receptors. These events lead to an accumulation of lipids, mainly cholesterol and cholesterol esters, in the macrophages, which will become lipid-laden foam cells. Foam cells may be considered the essence of the atheromatous lesions.
LDL are endowed with a number of lipid soluble antioxidants capable of preventing or minimizing lipid peroxidation. Plasma levels of CoQ 10 have been extensive investigated (Tomasetti et al., 1999) . Most plasma CoQ 10 is transported by LDL where, together with vitamin E, it exerts its antioxidant protection. Ubiquinol-10 is the most reactive antioxidant in LDL, and although it is present at lower concentrations compared to vitamin E, it is able to regenerate a-tocopherol from the tocopheril radical, making the vitamin E-ubiquinol duo the most important antioxidant system in LDL. CoQ 10 enriched LDL, isolated from plasma of healthy volunteers orally treated with CoQ 10 for a few days, were less susceptible to peroxidizability in vitro, compared to the same LDL in basal conditions (Mohr et al., 1992) .
Blood CoQ 10 is mainly transported by LDL, although it is also present in the other classes of lipoproteins and in blood cells. Its concentration is usually reported in micrograms/litre of plasma or micromoles/litre. But it is worthwhile to normalize these values according to the blood LDL content or at least to plasma cholesterol levels. The CoQ 10 /total cholesterol level could have a predictive value in cardiovascular disease (Molyneux et al., 2008) . Besides decreasing LDL peroxidizability, CoQ 10 could have a direct antiatherosclerotic effect, in fact animal studies have shown that CoQ 10 administration attenuates aortic atherosclerotic lesions (Witting et al. 2000 ; Singh et al. 2000) . Kon et al., 2008) . One of these articles shows that following a single administration of CoQ 10 plasma levels significantly correlated with muscle CoQ 10 levels, maximal oxygen consumption and treadmill time to exhaustion. A trend for increased time to exhaustion was observed following two weeks of CoQ 10 supplementation (p = 0.06) (Cooke et al., 2008) . In another trial, oral administration of CoQ 10 improved subjective fatigue sensation and physical performance (Mizuno et al., 2008) . The third article is a double blind study where a group of kendo athletes showed lower levels of CK, myoglobin and lipid peroxides compared to the corresponding values in the placebo group (Kon et al., 2008) .
Average daily intake through diet = 3 to 5 mg (Weber
In a study where CoQ 10 had been taken in combination with vitamin C and E, administration of this antioxidant cocktail further increased the eNOS and uncoupling protein 3 (UCP3) mRNA content after exercise (Hellsten et al., 2007) .
For the first time a study examined the acute effects of CoQ 10 and placebo on autonomic nervous activity and energy metabolism at rest and during exercise (Zheng and Moritani, 2008) . Fat oxidation significantly increased during exerciseintheCoQ 10 group;resultssuggested that CoQ 10 increases autonomic nervous activity during low intensity exercise.
In a double blind pilot study patients with post-polio syndrome were treated with 200 mg of CoQ 10 /day. Muscle strength, muscle endurance and quality of life increased statistically significantly in all 14 patients but there was no significant difference between the CoQ 10 and placebo groups (Kough et al., 2008) .
Effects on skin metabolism
The bioenergetic and antioxidant properties of CoQ 10 have also been studied at skin level. The first report was by Hoppe et al. (1999) . This paper demonstrated that CoQ 10 penetrates into the viable layers of the epidermis and reduces the levels of oxidation measured by weak photon emission. CoQ 10 was also effective in human keratinocytes against UVA mediated oxidative stress and in suppressing the expression of collagenase in human dermal fibroblasts following UVA irradiation. A reduction in wrinkle depth following CoQ 10 application was also shown, an effect confirmed by Ashida et al. (2005) . The combined effect of creatine and CoQ 10 on skin's energy metabolism was highlighted by Blatt et al. (2005) . Recently Inui and collaborators showed that cytokine production in keratinocytes is inhibited by CoQ 10 , resulting in a decrease of metalloproteinases leading to wrinkle reduction.
Reproductive medicine
Impairment of mitochondrial bioenergetics and oxidative stress are known to be involved in sperm motility. After a series of studies highlighting the implications of CoQ 10 in male infertility a more recent publication confirmed, in a placebo controlled double-blind randomized trial, the efficacy of CoQ 10 treatment in improving semen quality in men with idiopathic infertility (Balercia et al., 2009) . Oxidized and reduced CoQ 10 concentration significantly increased both in seminal plasma and sperm cells, together with sperm motility, after 6 months of therapy with 200 mg/day CoQ 10 . The increased concentration of CoQ 10 and QH 2 (reduced CoQ 10 ) in seminal plasma and sperm cells, the improvement of semen kinetic features and treatment, and the evidence of a direct correlation between CoQ 10 concentrations and sperm motility strongly support a cause-effect relationship. Similar results were found by Safarinejad (2009) . In this study 212 infertile men with idiopathic oligoasthenoteratospermia were treated with 300 mg/day CoQ 10 or placebo for 26 weeks. Statistically significant improvement was found, in the CoQ 10 group, regarding sperm count and motility values, with a positive correlation between treatment duration of CoQ 10 and sperm count as well as mean sperm motility. The CoQ 10 group had a significant decrease in serum FSH and LH at the 26 week treatment phase. The authors highlight that a lower serum FSH implies a better spermatogenesis. Moreover, Inhibin B, which reflects Sertoli's cell function, increased in the CoQ 10 group. These studies did not address the key issue of pregnancy rate; they were simply aimed at determining an effect of CoQ 10 on sperm motility and quality. Other variables should of course be taken into account in order to determine whether CoQ 10 has an influence on pregnancy rate.
CoQ 10 supports cardiovascular function CoQ 10 deficiency at myocardial level has been documented in different studies. Although in most cases the deficiency was not the cause of the cardiopathy this might have contributed to the severity of the disorder. Numerous trials have been conducted on the effect of CoQ 10 as coadjuvant in the treatment of cardiac failure. In many cases quality of life, clinical symptoms and the frequency of hospitalization were ameliorated upon CoQ 10 administration. In some protocols there was also an improvement of ejection fraction and other functional parameters.
Cardiovascular effects of CoQ 10 can be ascribed to its bioenergetic role, to its capability of antagonizing oxidation of plasma LDL and to its effect in ameliorating endothelial function. This effect was first seen by Watts et al. in patients affected by Type II diabetes (Watts et al., 2002) and then further explored by Belardinelli et al. in patients affected by ischemic heart disease (Belardinelli et al., 2006) . Endothelial dysfunction is commonly believed as an early sign of vascular impairment and the capability of CoQ 10 in counteracting it represents a promising field. The mild hypotensive effect of CoQ 10 is probably related to this property.
Human CoQ 10 deficiencies
Already in the past CoQ 10 had been shown to be effective in a number of cases of mitochondrial myopathies, which were sometimes associated with low CoQ 10 muscle levels. With the progress in molecular biology techniques primary CoQ 10 deficiencies, due to mutations in ubiquinone biosynthetic genes, have been identified and some of these syndromes have shown excellent responses to oral CoQ 10 treatment (Quinzii et al., 2008) .
Statins and CoQ 10
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors which decrease synthesis of mevalonate, a key metabolic step in the cholesterol synthesis pathway. These efficient drugs can produce a variety of muscle-related complaints or myopathies. Since the mevalonate pathway also leads to the biosynthesis of the isoprenoid side chain of coenzyme Q 10 , different studies have addressed the possibility of CoQ 10 being an etiologic factor in statin myopathy. There is no doubt that statins decrease plasma and leukocyte CoQ 10 levels; a few studies also report a decrease of muscle CoQ 10 level upon statin treatment. This controversial issue has been extensively investigated (Littarru and Langsjoen, 2007 ; Marcoff and Thompson, 2007) . A small-sized, yet double-blind study also points out that CoQ 10 exogenous administration reduced myopathic symptoms in statin treated patients (Caso et al., 2007) . Of course a large double blind clinical trail would be necessary in order to assess the capability of CoQ 10 in mitigating statin side effects.
Neurodegenerative disease
The positive effect of oral administration of CoQ 10 to patients affected by Parkinson's disease was investigated in 2002 by Shults et al. (2002) . Friedreich's ataxia is another condition where treatment with CoQ 10 and vitamin E caused a prolonged improvement in cardiac and skeletal muscle bioenergetics and clinical scores (Cooper and Schapira, 2007) .
In 2005 Sandor et al. studied the effect of CoQ 10 (300 mg/day for 3 months) in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. The primary outcome variable in this study was a change of attack frequency in the third month of treatment compared to baseline. The authors showed that responders were 47.6% in the CoQ 10 treated group vs 14.4% in the placebo group. A positive effect of CoQ 10 was also demonstrated in a large group of pediatric patients suffering from migraine (Hershey et al., 2007) .
Sourcing: main natural origins, Kaneka's process (yeast fermentation)
There are 3 methods used for the manufacturing of CoQ 10 : yeast fermentation, bacteria fermentation and chemical synthesis. The latter was the first industrial method, introduced by Nisshin in the early 70s. Greater amounts of CoQ 10 became available when Japanbased Kaneka Corporation began producing natural CoQ 10 (also called KANEKA Q10 TM ) via patented yeast fermentation in 1977. Kaneka is now the world's largest manufacturer of CoQ 10 and is the only producer to manufacture CoQ 10 in US market.
The yeast-fermentation method, along with Kaneka's rigorous manufacturing standards, makes KanekaQ10 TM the purest commercial-grade CoQ 10 available on the market today. The process results in CoQ 10 with the so-called alltrans configuration, which means that it is identical to naturally occurring CoQ 10 found in meat, fish and other products and also bio-identical to CoQ 10 produced in the human body (figure 5).
The Kaneka yeast fermentation process is in accordance with pharmaceutical GMP standards and does not contain impurities found in synthetic material.
Kaneka Q10
TM is the only CoQ 10 backed by published human safety studies and is the primary CoQ 10 used in most scientific studies. As purest, most rigorously tested CoQ 10 available, KanekaQ 10 has been used in all major CoQ 10 clinical trials approved by the FDA and funded by the NIH (e.g. Phase III Clinical Trial on Coenzyme Q 10 's Effects on Huntington's and Parkinson Disease in US).
Regulatory status
CoQ 10 is a well-established ingredient that is present in many food supplements, fortified foods and cosmetic brands all over Europe. There is an increasing acceptance of the role of non-vitamin and mineral ingredients, such as CoQ 10 and its levels move towards higher levels than were considered a decade ago based on risk assessment approach and supportive data. A Belgian ministerial order determined CoQ 10 was safe for use in food supplements at 200 mg after reviewing a dossier of Kaneka that provided scientific arguments to substantiate the safety of CoQ 10 up to 200 mg/day and higher. The 200 mg level is being followed by other European Union countries, and potentially all of them, by the legal principle of new Mutual Recognition Regulation. This Regulation requires products lawfully marketed in one EU member state to be permitted entry into another member state's market. The mutual recognition regulation plays a key role in the future EU market for CoQ 10 .
According the new European Health Claim regulation (EC 1924 (EC /2006 ) the generic health claims were planned to be disclosed in a positive list that EU would give access to by end of January 2010. Yet, early 2011 there is still no list available. In the meanwhile, national regulation still applies and all health claims that are well supported by science can continue to be used.
EFSA has started to deliver scientific opinions on art. 13 regarding generic health claims. EFSA is taking the stance to treat Vitamins and Minerals very differently from Other Substances -examples of the latter are CoQ 10 , glucosamine, lutein, lycopene, carnitine, etc. For Vitamins and Minerals a ''scientific consensus'' is usually sufficient to substantiate a health claim, whereas for Other Substances, golden standard human trials are required with conclusive evidence of cause and effect. Moreover, for Vitamins and Minerals EFSA accepts ''textbook'' knowledge as evidence.
As a general rule, EFSA does not accept human studies conducted on patients, yet medicinal paradigms are expected. Unfortunately, up to now, many CoQ 10 health benefits (as for other nutraceuticals) have been studied in patients. Because of this evolution, most generic claims for Other Substances have not been accepted by EFSA. This is also true for the generic CoQ 10 claims: energy, antioxidant, and blood pressure normalizing. We are facing a situation where study designs, which are acceptable in the scientific community, are not usable for marketing purposes.
Only in 2011 and 2012, which is more than 4 years after publication of the health claim regulation, EFSA will organise guidance meetings and publish documents to provide more clarity on their idea of how health claims should be substantiated for different fields such as weight management, cardiovascular health, joint health, physical performance, etc. Guidelines specifying the type of studies, the proper biomarkers to be used and other pertinent issues should also be established. The scientific community is just beginning to come to terms with health claim regulations and this process is ongoing. The full impact of the regulations is still evolving and many grey areas are apparent. An independent economic impact assessment of existing and potential effects of the health claims regulation concluded that all initial objectives of the health claims regulation, notably relating to objectives such as consumer protection, fair competition, and promotion of R&D, were only poorly or weakly addressed (Brookes, 2010) .
Ubiquinol
Ubiquinol, the reduced form of CoQ 10 has recently become available in stable form, and is manufactured exclusively by Kaneka. Ubiquinol represents 93-95% of CoQ 10 pool in plasma of healthy human and is the predominant Coenzyme Q 10 form in a healthy cell. Several studies suggest that ubiquinol-ratio in human plasma may represent a sensitive index of oxidative stress in vivo especially indicative of early oxidative damage. CoQ 10 researchers from around the world are working to advance the understanding of the newly available ubiquinol. Recently, Japanese researchers showed protective effects of ubiquinol on influenza virus infection in mice.
Conclusion
CoQ 10 is a highly studied nutrient whose biochemical and physiological role has been established. What is special about this molecule is its involvement both in the bioenergetic and in the antioxidant processes. While waiting for a definite pronunciation by the European authorities, national regulations still apply and the number of health claims that are well supported by science can continue to be used.
